Anfield Capital Management’s BioNTech BNTX Stock Holding History

Anfield Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,004	Closed	-$151K	–	72
2022 Q4	$151K	Sell	1,004 -819	-45%	-$126K	0.07%	70
2022 Q3	$246K	Buy	1,823 +63	+4%	+$9.63K	0.12%	67
2022 Q2	$262K	Buy	1,760 +252	+17%	+$38.5K	0.12%	66
2022 Q1	$257K	Buy	1,508 +1,072	+246%	+$180K	0.09%	72
2021 Q4	$112K	Buy	436 +398	+1,047%	+$109K	0.04%	79
2021 Q3	$10K	Buy	+38	New	+$12.1K	﹤0.01%	93

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Anfield Capital Management's BNTX Position: Q1 2023 in Review

Anfield Capital Management sold out of BioNTech (BNTX) in Q1 2023, closing a stake of 1,004 shares — an estimated $151K sold.

Anfield Capital Management first reported a position in BNTX in Q3 2021 and held it in 6 quarters. The position peaked at $262K in Q2 2022. 282 funds tracked by Wall St. Rank hold BNTX as of Q1 2023.

Anfield Capital Management reported no remaining BioNTech position as of Q1 2023 after selling out during the quarter.
Anfield Capital Management sold 1,004 BioNTech shares in Q1 2023, an estimated $151K.
Anfield Capital Management first reported a position in BioNTech in Q3 2021 and held it in 6 quarters.
Anfield Capital Management's BioNTech position peaked at $262K in Q2 2022.
282 funds tracked by Wall St. Rank held BioNTech as of Q1 2023.

Based on Anfield Capital Management's 13F filing for Q1 2023, filed 4 May 2023.